CN111887242A - Normal-temperature cell storage and transportation method and application thereof - Google Patents
Normal-temperature cell storage and transportation method and application thereof Download PDFInfo
- Publication number
- CN111887242A CN111887242A CN202010850936.9A CN202010850936A CN111887242A CN 111887242 A CN111887242 A CN 111887242A CN 202010850936 A CN202010850936 A CN 202010850936A CN 111887242 A CN111887242 A CN 111887242A
- Authority
- CN
- China
- Prior art keywords
- transportation
- cell
- normal
- temperature
- cell storage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000003860 storage Methods 0.000 title claims abstract description 64
- 238000000034 method Methods 0.000 title claims abstract description 38
- 239000000243 solution Substances 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 claims abstract description 12
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 10
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 10
- 239000003792 electrolyte Substances 0.000 claims abstract description 10
- 239000007924 injection Substances 0.000 claims abstract description 10
- 238000002347 injection Methods 0.000 claims abstract description 10
- 239000002904 solvent Substances 0.000 claims abstract description 9
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 claims abstract description 4
- 239000000047 product Substances 0.000 claims abstract description 4
- 239000012264 purified product Substances 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 72
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 238000009533 lab test Methods 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000004083 survival effect Effects 0.000 abstract description 3
- 239000002504 physiological saline solution Substances 0.000 abstract 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a normal-temperature cell storage and transportation method and application thereof, and the normal-temperature cell storage and transportation method specifically comprises the following steps: placing cells to be stored and transported in a cell storage and transportation solution, wherein the cell storage and transportation solution contains a cell basic solvent, and the cell basic solvent is physiological saline, compound physiological saline, lactated ringer's solution or compound electrolyte injection; the cell storage and transportation liquid also contains 5-10% by mass of human serum albumin which is a plasma purified product or a recombinant product; the cell storage and transportation liquid is suitable for low-temperature and normal-temperature cell transportation, and preferably normal-temperature cell transportation. The invention can realize normal temperature or low temperature storage and transportation only by placing the cells to be stored and transported in the cell storage and transportation liquid. The invention adjusts and improves the cell storage liquid used for storing cells in the prior art to realize the cell storage and transportation for less than 48 hours at normal temperature, and can be butted with laboratory experiments/production and clinical application on the premise of ensuring the cell survival rate.
Description
Technical Field
The invention belongs to the technical field of cell storage and transportation methods, and particularly relates to a normal-temperature cell storage and transportation method and application thereof.
Background
In general, cells can keep alive for a long time under the conditions of cryoprotectants or liquid nitrogen, but the commercial cell cryopreservation agent in the prior art usually contains 5-10% of dimethyl sulfoxide (DMSO) and is not suitable for the requirement of clinical application. In the prior art, living cells and preparations thereof are generally stored and transported at a low temperature of 4-8 ℃, and researches show that a complete cell culture medium or Phosphate Buffered Saline (PBS) can better preserve the cell Viability (Viability) in the short-time storage and transportation process of the cells, namely 24-48 hours, at a normal temperature (23 +/-2 ℃), but the cell culture medium or the PBS is not suitable for clinical application requirements. When the cell storage and transportation box is used for low-temperature storage and transportation, the cell storage and transportation box with a special structure is usually used, and a temperature and humidity monitoring system is also required to be arranged on the cell storage and transportation box so as to monitor the temperature and the humidity in the cell storage and transportation box in real time and ensure the survival rate of cells in the cell storage and transportation box. The low-temperature storage and transportation causes higher storage and transportation cost, and the storage and transportation container and the storage and transportation process are more complicated. If the method for storing and transporting the cells at the normal temperature and the application thereof can be provided, the method becomes a great breakthrough of the method for storing and transporting the cells.
Disclosure of Invention
The invention provides a normal-temperature cell storage and transportation method and application thereof, aiming at overcoming the defects in the prior art.
The invention is realized by the following technical scheme: the invention discloses a normal-temperature cell storage and transportation method, which specifically comprises the following steps:
(1) placing cells to be stored and transported in a cell storage and transportation solution, wherein the cell storage and transportation solution contains a cell basic solvent, and the cell basic solvent is normal saline, compound normal saline, lactated ringer's solution or compound electrolyte injection;
(2) the cell storage and transportation liquid also contains 5-10% by mass of human serum albumin which is a plasma purified product or a recombinant product;
(3) the cell storage and transportation liquid is suitable for low-temperature and normal-temperature cell transportation, and preferably normal-temperature cell transportation.
The normal saline is NaCl solution with the mass percent of 0.9%.
The compound normal saline is ringer's solution, wherein each 100ml of ringer's solution contains 0.82-0.90 g of sodium chloride, 0.025-0.035 g of potassium chloride and 0.03-0.036 g of calcium chloride.
The compound electrolyte injection adopts Bomaili compound electrolyte injection (Plasma-LyteA).
The human serum albumin is preferably recombinant human serum albumin.
The normal-temperature cell storage and transportation method disclosed by the invention is suitable for short-time storage and transportation of less than 48 hours.
The invention also discloses an application of the normal-temperature cell storage and transportation method, and the normal-temperature cell storage and transportation method is applied to storage and transportation of cancer cells or tumor infiltrating lymphocytes.
Cell therapy (cell therapy) refers to a treatment mode in which certain cells with specific functions are obtained by a bioengineering method and/or are treated by in vitro amplification, special culture and the like, and then are transfused back to a patient. Immune cells (leukocytes), also known as leukocytes, refer to all cells involved in immune responses, mainly including lymphocytes and various phagocytic cells, and the like, which are functional units of the immune system. Immune cells are commonly used for the treatment of tumors. TIL (tumor-infiltrating lymphocytes) is a T cell which infiltrates into tumor tissues and can effectively identify tumor cell neoantigens. The T cell capable of recognizing the tumor cell neoantigen has the capacity of efficiently killing tumor cells, including killing tumor passage cells transferred to other parts from the focus.
In the immune cell therapy, the cancer cells or tumor infiltrating lymphocytes of a patient need to be stored and transported for a short time, and the prior art adopts low-temperature storage and transportation with higher cost. The normal-temperature storage and transportation method can reduce the storage and transportation cost of cancer cells and tumor infiltrating lymphocytes and reduce more treatment cost for cancer patients.
The invention has the beneficial effects that: in the prior art, living cells and preparations thereof are generally stored and transported at a low temperature of 4-8 ℃, and a cell solvent is adjusted to be in butt joint with laboratory experiments/production and clinical application. The normal-temperature cell storage and transportation method disclosed by the invention can realize normal-temperature or low-temperature storage and transportation only by placing cells to be stored and transported in the cell storage and transportation solution. The invention adjusts and improves the cell storage liquid used for storing cells in the prior art to realize the cell storage and transportation for less than 48 hours at normal temperature, and can be butted with laboratory experiments/production and clinical application on the premise of ensuring the cell survival rate.
Detailed Description
The present invention will be described in detail with reference to specific embodiments.
The invention discloses a normal-temperature cell storage and transportation method, which specifically comprises the following steps: (1) placing cells to be stored and transported in a cell storage and transportation solution, wherein the cell storage and transportation solution contains a cell basic solvent, and the cell basic solvent is normal saline, compound normal saline, lactated ringer's solution or compound electrolyte injection; (2) the cell storage and transportation liquid also contains 5-10% by mass of human serum albumin which is a plasma purified product or a recombinant product; (3) the cell storage and transportation liquid is suitable for low-temperature and normal-temperature cell transportation, and preferably normal-temperature cell transportation.
The normal saline is NaCl solution with the mass percent of 0.9%. The compound normal saline is ringer's solution, wherein each 100ml of ringer's solution contains 0.82-0.90 g of sodium chloride, 0.025-0.035 g of potassium chloride and 0.03-0.036 g of calcium chloride. The compound electrolyte injection adopts Bomaili compound electrolyte injection (Plasma-LyteA). The human serum albumin is preferably recombinant human serum albumin. The normal-temperature cell storage and transportation method disclosed by the invention is suitable for short-time storage and transportation of less than 48 hours. The invention also discloses an application of the normal-temperature cell storage and transportation method, and the normal-temperature cell storage and transportation method is applied to storage and transportation of cancer cells or tumor infiltrating lymphocytes.
Finally, it should be noted that the above contents are only used to illustrate the technical solutions of the present invention, and do not limit the protection scope of the present invention. Simple modifications and equivalents may be made by those skilled in the art without departing from the spirit and scope of the present invention.
Claims (7)
1. A normal-temperature cell storage and transportation method is characterized in that: the normal-temperature cell storage and transportation method specifically comprises the following steps:
(1) placing cells to be stored and transported in a cell storage and transportation solution, wherein the cell storage and transportation solution contains a cell basic solvent, and the cell basic solvent is normal saline, compound normal saline, lactated ringer's solution or compound electrolyte injection;
(2) the cell storage and transportation liquid also contains 5-10% by mass of human serum albumin which is a plasma purified product or a recombinant product;
(3) the cell storage and transportation liquid is suitable for low-temperature and normal-temperature cell transportation.
2. The method of claim 1, wherein the method comprises: the normal saline is NaCl solution with the mass percentage of 0.9%.
3. The method of claim 1, wherein the method comprises: the compound normal saline is ringer's solution, and each 100ml of ringer's solution contains 0.82-0.90 g of sodium chloride, 0.025-0.035 g of potassium chloride and 0.03-0.036 g of calcium chloride.
4. The method of claim 1, wherein the method comprises: the compound electrolyte injection adopts Bomaili compound electrolyte injection.
5. The method of claim 1, wherein the method comprises: the human serum albumin is recombinant human serum albumin.
6. The method of claim 1, wherein the method comprises: the normal-temperature cell storage and transportation method is suitable for short-time storage and transportation of less than 48 hours.
7. Use of a method for transporting and storing normothermic cells according to any one of claims 1 to 6, wherein: the normal-temperature cell storage and transportation method is applied to storage and transportation of cancer cells or tumor infiltrating lymphocytes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010850936.9A CN111887242A (en) | 2020-08-21 | 2020-08-21 | Normal-temperature cell storage and transportation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010850936.9A CN111887242A (en) | 2020-08-21 | 2020-08-21 | Normal-temperature cell storage and transportation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111887242A true CN111887242A (en) | 2020-11-06 |
Family
ID=73229885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010850936.9A Pending CN111887242A (en) | 2020-08-21 | 2020-08-21 | Normal-temperature cell storage and transportation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111887242A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113120390A (en) * | 2021-05-12 | 2021-07-16 | 恩大细胞基因工程有限公司 | Method for storing and transporting cells at normal temperature |
-
2020
- 2020-08-21 CN CN202010850936.9A patent/CN111887242A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113120390A (en) * | 2021-05-12 | 2021-07-16 | 恩大细胞基因工程有限公司 | Method for storing and transporting cells at normal temperature |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jing et al. | Organ preservation: from the past to the future | |
| JP3165863B2 (en) | Cryopreservation solution | |
| Ma et al. | Advanced biomaterials in cell preservation: Hypothermic preservation and cryopreservation | |
| CN108207930B (en) | Cocktail type cryoprotectant and application thereof | |
| Buchanan et al. | Preservation of differentiation and clonogenic potential of human hematopoietic stem and progenitor cells during lyophilization and ambient storage | |
| Jitraruch et al. | Cryopreservation of hepatocyte microbeads for clinical transplantation | |
| Knaak et al. | Technique of subnormothermic ex vivo liver perfusion for the storage, assessment, and repair of marginal liver grafts | |
| Salehi et al. | Focus: Medical Technology: Advances in Perfusion Systems for Solid Organ Preservation | |
| Duan et al. | Adult multipotent stromal cell cryopreservation: pluses and pitfalls | |
| CN111248191A (en) | Normal-temperature cell preservation solution and cell preparation for injection | |
| Cypel et al. | Extracorporeal lung perfusion | |
| Njoku et al. | Haemoglobin-based oxygen carriers: indications and future applications | |
| CN112167240A (en) | Clinical grade cell cold storage preservation solution and preparation method and application thereof | |
| Bonaccorsi-Riani et al. | Machine perfusion: cold versus warm, versus neither. update on clinical trials | |
| López-Martínez et al. | Normothermic machine perfusion systems: where do we go from here? | |
| Bellomo et al. | Normothermic extracorporeal perfusion of isolated porcine liver after warm ischaemia: a preliminary report | |
| CN111602648B (en) | Immune cell serum-free cryopreservation liquid and cryopreservation method | |
| US20220354108A1 (en) | Preservation methods using trehalose with other cryoprotectants being absent from the cryopreservation protocol | |
| Freitas-Ribeiro et al. | Long-term and short-term preservation strategies for tissue engineering and regenerative medicine products: state of the art and emerging trends | |
| CN111887242A (en) | Normal-temperature cell storage and transportation method and application thereof | |
| CN109511649B (en) | Normal-temperature mechanical perfusion system capable of expanding liver supply source | |
| CN112167241A (en) | Stem cell freezing medium and stem cell freezing and recovering method | |
| Hatayama et al. | Preservation by desiccation of isolated rat hearts for 48 hours using carbon monoxide (PCO= 4,000 hPa) and oxygen (PO2= 3,000 hPa) | |
| CN115349515A (en) | Cell preservation solution and cell preservation method | |
| CN111449053A (en) | Immune cell storage liquid and preparation and application methods thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201106 |
|
| WD01 | Invention patent application deemed withdrawn after publication |